Cogstate Limited (COGZF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cogstate Limited (COGZF) with AI Score 45/100 (Weak). Cogstate Limited provides computerized cognitive tests and electronic clinical outcome assessment solutions. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Cogstate Limited (COGZF) Healthcare & Pipeline Overview
Cogstate Limited, a neuroscience technology company, offers computerized cognitive assessment solutions for clinical trials and healthcare. With a focus on early detection of cognitive decline, Cogstate serves pharmaceutical companies and healthcare providers, leveraging its proprietary Cognigram system and data management expertise in a growing market.
Investment Thesis
Cogstate Limited presents a compelling investment case based on its established position in the growing market for cognitive assessment solutions. With a P/E ratio of 21.95 and a profit margin of 19.6%, the company demonstrates solid profitability. Key value drivers include the increasing demand for cognitive testing in clinical trials and healthcare settings, driven by an aging population and growing awareness of cognitive disorders. Growth catalysts include expanding the adoption of Cognigram in primary care and hospitals, as well as securing new contracts in the clinical trials segment. Potential risks include competition from other cognitive assessment providers and regulatory changes in the healthcare industry. The company's dividend yield of 0.93% offers a modest return to investors.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.27B reflects Cogstate's current valuation in the market.
- P/E Ratio of 21.95 indicates the price investors are willing to pay for each dollar of Cogstate's earnings.
- Profit Margin of 19.6% demonstrates Cogstate's ability to generate profit from its revenue.
- Gross Margin of 34.8% shows the percentage of revenue exceeding the cost of goods sold.
- Beta of -0.02 suggests Cogstate's stock price has very low volatility relative to the overall market.
Competitors & Peers
Strengths
- Proprietary cognitive assessment technology.
- Established relationships with pharmaceutical companies.
- Extensive database of cognitive assessment data.
- Experienced team of scientists and clinicians.
Weaknesses
- Limited geographic reach.
- Dependence on clinical trial market.
- Relatively small market capitalization.
- OTC listed, which may limit investor access.
Catalysts
- Ongoing: Increasing adoption of Cognigram in primary care settings for early detection of cognitive decline.
- Ongoing: Expansion of clinical trial services to pharmaceutical and biotechnology companies.
- Upcoming: Potential partnerships with healthcare providers to broaden market reach.
- Upcoming: Development and launch of new cognitive assessment tools.
- Ongoing: Leveraging data analytics to provide insights to pharmaceutical companies and healthcare providers.
Risks
- Potential: Competition from other cognitive assessment providers.
- Potential: Regulatory changes in the healthcare industry.
- Potential: Economic downturn affecting clinical trial spending.
- Potential: Technological advancements rendering current solutions obsolete.
- Ongoing: Risks associated with operating in the OTC market, including limited liquidity and disclosure.
Growth Opportunities
- Expanding Cognigram Adoption in Healthcare: Cogstate has the opportunity to increase the adoption of its Cognigram system in primary care and hospitals. The market for early detection of cognitive decline is growing, driven by an aging population and increased awareness of conditions like Alzheimer's disease. By partnering with healthcare providers and demonstrating the clinical and economic benefits of Cognigram, Cogstate can capture a larger share of this market. This expansion could significantly increase revenue within the next 3-5 years, with a potential market size exceeding $1 billion.
- Securing New Clinical Trial Contracts: The clinical trials segment represents a significant growth opportunity for Cogstate. As pharmaceutical and biotechnology companies continue to invest in the development of new treatments for neurological and psychiatric disorders, the demand for cognitive assessment solutions in clinical trials will increase. By leveraging its expertise in data management, scientific consulting, and statistical analysis, Cogstate can secure new contracts with these companies and expand its presence in the clinical trials market. This growth is expected to continue over the next 5-10 years, with the global clinical trials market projected to reach $69 billion by 2028.
- Geographic Expansion: Cogstate has the opportunity to expand its geographic reach by entering new markets in Asia, Europe, and South America. These regions are experiencing rapid economic growth and increasing healthcare spending, creating a favorable environment for the adoption of cognitive assessment solutions. By establishing partnerships with local distributors and healthcare providers, Cogstate can penetrate these markets and diversify its revenue streams. This expansion could contribute to significant revenue growth within the next 2-4 years.
- Developing New Cognitive Assessment Tools: Cogstate can drive growth by developing new cognitive assessment tools that address unmet needs in the market. This could include tools for assessing specific cognitive domains, such as memory, attention, and executive function, or tools for use in specific populations, such as children or older adults. By investing in research and development and collaborating with leading experts in the field, Cogstate can create innovative solutions that differentiate it from competitors and attract new customers. The timeline for developing and launching new tools is approximately 1-3 years.
- Leveraging Data Analytics: Cogstate can leverage its extensive database of cognitive assessment data to provide valuable insights to pharmaceutical companies and healthcare providers. By offering data analytics services, such as predictive modeling and risk stratification, Cogstate can help these organizations improve their decision-making and optimize their clinical trial designs and treatment strategies. This represents a significant growth opportunity, as the demand for data-driven healthcare solutions continues to increase. The market for healthcare analytics is projected to reach $75 billion by 2026.
Opportunities
- Expanding Cognigram adoption in healthcare.
- Securing new clinical trial contracts.
- Geographic expansion into new markets.
- Developing new cognitive assessment tools.
Threats
- Competition from other cognitive assessment providers.
- Regulatory changes in the healthcare industry.
- Economic downturn affecting clinical trial spending.
- Technological advancements rendering current solutions obsolete.
Competitive Advantages
- Proprietary Cognitive Assessment Technology: Cogstate's computerized cognitive tests and Cognigram system are based on proprietary technology and algorithms, providing a competitive advantage.
- Established Relationships with Pharmaceutical Companies: Cogstate has established long-term relationships with leading pharmaceutical companies, creating a barrier to entry for new competitors.
- Extensive Database of Cognitive Assessment Data: Cogstate has accumulated a large database of cognitive assessment data, which can be used to improve its products and services and provide valuable insights to customers.
- Scientific Expertise: Cogstate has a team of experienced scientists and clinicians who are experts in the field of cognitive assessment.
About COGZF
Cogstate Limited, founded in 1999 and based in Melbourne, Australia, is a neuroscience technology company specializing in computerized cognitive tests and electronic clinical outcome assessment solutions. The company operates through two primary segments: Clinical Trials and Healthcare. The Clinical Trials segment provides technology and associated services used to quantify the effects of diseases, drugs, devices, and other interventions on human subjects participating in clinical trials, primarily conducted by pharmaceutical and biotechnology companies. This includes project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. The Healthcare segment offers Cognigram, a system designed for regular and standardized testing to assist primary care physicians and hospitals in the early detection of cognitive decline. Cogstate has participated in approximately 1,800 academic research studies as of June 30, 2022. The company's solutions aid in the development of new treatments and improve patient care by providing reliable and sensitive cognitive assessments.
What They Do
- Provides computerized cognitive tests for clinical trials.
- Offers electronic clinical outcome assessment solutions.
- Assists in quantifying the effects of diseases and treatments on cognitive function.
- Provides Cognigram, a system for early detection of cognitive decline.
- Offers project management and data management services for clinical trials.
- Provides scientific consulting and statistical analysis.
- Offers scales procurement, rater training, and monitoring solutions.
Business Model
- Generates revenue from clinical trial services provided to pharmaceutical and biotechnology companies.
- Earns revenue from the sale and implementation of Cognigram to healthcare providers.
- Provides data management and statistical analysis services.
- Offers consulting services related to cognitive assessment.
Industry Context
Cogstate Limited operates in the healthcare information services industry, which is experiencing growth due to the increasing demand for digital health solutions and cognitive assessment tools. The market is driven by factors such as an aging population, rising prevalence of cognitive disorders, and the need for more efficient and accurate diagnostic methods. The competitive landscape includes companies like BHHKF (BioHiTech Global, Inc.), CLVLF (Clarity Life Sciences Inc.), CMVLF (Clearmind Medicine Inc.), EAPIF (Enveric Biosciences, Inc.), and EDTXF (EdtechX Holdings Acquisition Corp.), each offering various solutions in the healthcare and biotechnology sectors. Cogstate differentiates itself through its focus on computerized cognitive testing and its established presence in both clinical trials and healthcare settings.
Key Customers
- Pharmaceutical companies conducting clinical trials.
- Biotechnology companies developing new treatments.
- Hospitals and primary care physicians using Cognigram for early detection of cognitive decline.
- Academic researchers studying cognitive function.
Financials
Chart & Info
Cogstate Limited (COGZF) stock price: Price data unavailable
Latest News
-
3 ASX Growth Stocks With High Insider Ownership And 51% Revenue Growth
Simply Wall St. · Feb 15, 2026
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for COGZF.
Price Targets
Wall Street price target analysis for COGZF.
MoonshotScore
What does this score mean?
The MoonshotScore rates COGZF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Bradley John O'Connor
Unknown
Bradley John O'Connor is the managing director of Cogstate Limited, overseeing the company's operations and strategic direction. His leadership is pivotal in guiding the company's growth within the neuroscience technology sector. His responsibilities include managing the company's 147 employees and driving the development and commercialization of Cogstate's cognitive assessment solutions. Further details regarding his career history, education, and previous roles are not available in the provided data.
Track Record: Information on Bradley John O'Connor's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided data. His role involves managing the company's operations and driving the development and commercialization of Cogstate's cognitive assessment solutions.
COGZF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cogstate Limited (COGZF) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. This tier is often associated with higher risks due to the potential for less transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The lack of comprehensive financial reporting increases the difficulty in assessing the company's financial health.
- Lower Liquidity: Reduced trading volume and wider bid-ask spreads can make it challenging to buy or sell shares at desired prices.
- Regulatory Scrutiny: OTC-listed companies may face less regulatory oversight, increasing the risk of fraud or mismanagement.
- Price Volatility: The potential for significant price swings due to lower trading volumes and market speculation.
- Delisting Risk: Failure to meet minimum listing requirements could result in delisting from the OTC market.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Research the background and experience of the management team.
- Evaluate the company's risk factors and potential liabilities.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established Business Operations: Cogstate Limited has been in operation since 1999, indicating a history of business activity.
- Participation in Academic Research: The company has participated in approximately 1,800 academic research studies, suggesting scientific credibility.
- Focus on Healthcare: Cogstate operates in the healthcare sector, which is subject to regulatory oversight and standards.
- Partnerships with Pharmaceutical Companies: The company's relationships with pharmaceutical companies suggest a level of industry acceptance.
Cogstate Limited Stock: Key Questions Answered
What does Cogstate Limited do?
Cogstate Limited is a neuroscience technology company that provides computerized cognitive tests and electronic clinical outcome assessment solutions. It operates in two segments: Clinical Trials and Healthcare. In Clinical Trials, Cogstate offers technology and services to quantify the effects of diseases and treatments on cognitive function, primarily for pharmaceutical and biotechnology companies. In Healthcare, it provides Cognigram, a system for early detection of cognitive decline in primary care and hospital settings. The company's solutions aid in the development of new treatments and improve patient care by providing reliable cognitive assessments.
What do analysts say about COGZF stock?
AI analysis is pending for COGZF, so an analyst consensus is not currently available. Key valuation metrics include a P/E ratio of 21.95, a profit margin of 19.6%, and a dividend yield of 0.93%. Growth considerations include the increasing demand for cognitive assessment solutions in clinical trials and healthcare, as well as the company's ability to expand its market reach and develop new products. Investors should conduct their own research and consider their individual risk tolerance before making any investment decisions.
What are the main risks for COGZF?
The main risks for Cogstate Limited include competition from other cognitive assessment providers, regulatory changes in the healthcare industry, and the potential for an economic downturn to affect clinical trial spending. Additionally, technological advancements could render the company's current solutions obsolete. As an OTC-listed company, COGZF also faces risks associated with limited liquidity and disclosure, which can increase price volatility and make it more difficult to assess the company's financial health. Investors should carefully consider these risks before investing in COGZF.
What are the key factors to evaluate for COGZF?
Cogstate Limited (COGZF) currently holds an AI score of 45/100, indicating low score. Key strength: Proprietary cognitive assessment technology.. Primary risk to monitor: Potential: Competition from other cognitive assessment providers.. This is not financial advice.
How frequently does COGZF data refresh on this page?
COGZF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven COGZF's recent stock price performance?
Recent price movement in Cogstate Limited (COGZF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary cognitive assessment technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider COGZF overvalued or undervalued right now?
Determining whether Cogstate Limited (COGZF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying COGZF?
Before investing in Cogstate Limited (COGZF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-17.
- AI analysis is pending for COGZF.
- OTC market data may be less reliable than major exchange data.